CSIMarket

Predictive Oncology Inc. Achieves Remarkable Results in Fiscal First Quarter of 2024

Overcoming Losses with Impressive Revenue Growth


Published / Modified May 15 2024
Goran Soko / CSIMarket.com


Predictive Oncology Inc., a leading medical equipment and supplies company, recently reported its financial results for the first quarter of 2024.
During this period, the company experienced increased losses per share compared to the previous year, with a deficit of $-1.04 per share, compared to $-0.86 in the same period last year.
Additionally, the deficit was higher than the preceding reporting period.

Despite the increased losses, Predictive Oncology Inc.
saw a strong increase in revenue, which rose by 74.929% to $0.42 million, up from $0.24 million in the same reporting period a year ago.
Sequentially, the company's revenue also improved by 25.255% from $0.34 million.
This
growth in revenue is particularly noteworthy when compared to other companies in the Medical Equipment & Supplies sector, which only experienced a 6.53% increase in revenue during the same period.

However, the net deficit for the first quarter of 2024 was larger than the previous year, with Predictive Oncology Inc.
realizing a deficit of $-4.219 million, compared to $-3.422 million in the same period last year.

In a recent announcement, the company revealed its collaboration with FluGen, a groundbreaking project aiming to develop a first-of-its-kind intranasal flu vaccine.
This project has received a significant boost with the support of a $6.2 million Phase 2B grant from the United States Department of Defense (DoD).
The intranasal flu vaccine offers potential advantages over traditional flu shots, such as ease of administration and enhanced patient compliance.

Despite the positive news surrounding the collaboration, Predictive Oncology Inc.
has seen a decrease in its stock performance.
In May,
the company's stock went down by -1.21%, bringing the year-to-date performance to -53.76%. Currently, the stock is trading on NASDAQ at -51.9% below its 52-week average.

In light of these financial results and developments, Predictive Oncology Inc.
will be hosting an investor call and webcast today at 8:30 am EDT.
This presents an opportunity for investors and stakeholders to gain insights into the company's future plans and strategies.

Overall, while Predictive Oncology Inc.
has experienced increased losses and a decline in stock performance, the company's revenue growth and collaboration with FluGen offer potential for future success in the medical equipment and supplies sector.



Predictive Oncology Inc's Executive Officers

Predictive Oncology Inc's Executive Officers



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com